

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Last Update: Apr 18, 2025

A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase

ClinicalTrials.gov Identifier:

[NCT05142696](#)

Novartis Reference Number:CAAA601A42101

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This study aims to establish a safe and well tolerated dose of [177Lu]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab. The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type. The study for each participant consists of a Screening period, a Treatment period that includes an Induction treatment period and a Maintenance treatment period, and a Follow-up period.

The study will consist of a Phase Ib dose escalation with concurrent backfill part and a randomised controlled Phase II part.

During the screening period of up to 28 days before starting SCLC treatment, each participant will be assessed for somatostatin receptor (SSTR) expression by [68Ga]Ga-DOTA-TATE imaging PET/scan.

The dose escalation part in this study will be guided by the dose limiting toxicity (DLT) rate observed during the DLT period. To achieve a more robust dataset and to aid dose decisions, additional participants may be backfilled in each dose level.

Upon declaring RD, a 1:1 randomised Phase II with approximately 140 participants with newly diagnosed ES-SCLC will be enrolled and receive either [177Lu]Lu-DOTA-TATE at the RD in combination with carboplatin, etoposide and atezolizumab (experimental arm) or carboplatin, etoposide and atezolizumab alone (control arm).

Condition

Extensive Stage Small Cell Lung Cancer

Phase

Phase1, Phase2

Overall Status

Recruiting

Number of Participants

200

Start Date

Jul 13, 2022

Completion Date

Mar 23, 2029

Gender

All

Age(s)

18 Years - 100 Years (Adult, Older Adult)

Interventions

Drug

Atezolizumab

Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period

Other

Carboplatin

Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period

Other

Etoposide

Four cycles of etoposide 100 mg/m² on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period

Drug

[177Lu]Lu-DOTA-TATE

Solution for infusion of ¹⁷⁷Lu-DOTA-TATE will be administered as follows: * 2 administrations during the induction period on either Day 3, 4 or 5 of Week 1 and on Week 7 Day 3 * 1 to 4 administrations during the maintenance period on Week 13 Day 1, Week 16 Day 1, Week 19 Day 1 and Week 22 Day 1, depending on the dose assessed

Drug

[68Ga]Ga-DOTA-TATE

2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)

Eligibility Criteria

Key Inclusion Criteria:

* Participant is \geq 18 years on the day of signing informed consent form

- * Histologically or cytologically confirmed ES-SCLC
- * Presence of measurable disease (at least one target lesion) according to RECIST v1.1 assessed by conventional computed tomography (CT) scan
- * No prior systemic treatment for ES-SCLC (except the first cycle of chemotherapy with or without atezolizumab of the induction period)
- * ECOG status ≤ 1
- * Provision of tumor tissue to support exploratory biomarker analysis
- * Life expectancy of ≥ 6 months

Key Exclusion Criteria:

- * Participant has received prior therapy with an antibody or drug against immune checkpoint pathways
- * Active autoimmune diseases or history of autoimmune diseases that may relapse
- * Severe chronic or active infections (including active tuberculosis, HBV, or HCV infection) requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks before Cycle 1 Day 1
- * Any major surgical procedure requiring general anesthesia ≤ 28 days before Cycle 1 Day 1
- * History or current diagnosis of electrocardiogram (ECG) abnormalities indicating significant risk of safety for participants participating in the study
- * Known hypersensitivity to the active substances or any of the excipients of the study drugs
- * Concurrent participation in another therapeutic clinical study

France

Novartis Investigative Site

Recruiting

Montpellier,34298,France

Novartis Investigative Site

Recruiting

Villejuif,94800,France

Novartis Investigative Site

Recruiting

Lille,59000,France

Novartis Investigative Site

Recruiting

Marseille,13885,France

Germany

Novartis Investigative Site

Recruiting

Essen,45147,Germany

Novartis Investigative Site

Recruiting

Koeln,50937,Germany

Israel

Novartis Investigative Site

Recruiting

Haifa,3109601,Israel

Novartis Investigative Site

Recruiting

Tel Aviv,6423906,Israel

Singapore

Novartis Investigative Site

Recruiting

Singapore,168583,Singapore

Spain

Novartis Investigative Site

Recruiting

Madrid,28009,Spain

Novartis Investigative Site

Recruiting

Madrid,28041,Spain

Novartis Investigative Site

Recruiting

Malaga,Andalucia,29010,Spain

Novartis Investigative Site

Recruiting

Barcelona,Catalunya,08035,Spain

United Kingdom

Novartis Investigative Site

Recruiting

Guildford,Surrey,Gu2 7xx,United Kingdom

United States

Fox Chase Cancer Center

Recruiting

Philadelphia,Pennsylvania,19111,United States

Lakeesha Dawson

Phone: 215-728-5534

Email: Lakeesha.Dawson@fccc.edu

Martin J Edelman

University of Kentucky

Recruiting

Lexington,Kentucky,40536,United States

Phone: 859-218-5151

Zhonglin Hao

University Hospitals Of Cleveland

Recruiting

Cleveland,Ohio,44106,United States

Afshin Dowlati

Daria Brausch

Email: daria.brausch@uhhospitals.org

University Cancer and Blood Center LLC

Recruiting

Athens,Georgia,30607,United States

Laurie Bridges

Phone: [706-353-5006](tel:706-353-5006)

Email: laurie.bridges@universitycancer.com

Petros Nikolinos

Hackensack Meridian Health

Recruiting

Edison, New Jersey, 08837, United States

Dunlu Chen

Phone: [732-836-4190](tel:732-836-4190)

Email: dunlu.chen@hackensackumc.org

Martin E Gutierrez

Georgetown University Lombardi Cancer Center

Recruiting

Washington, District of Columbia, 20007 2197, United States

Ashlyn Wallace

Phone: [202-687-8676](tel:202-687-8676)

Email: aew72@georgetown.edu

Chul Kim

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: [+41613241111](tel:+41613241111)

Email:

Novartis Pharmaceuticals

Phone: [1-888-669-6682](tel:1-888-669-6682)

Email: novartis.email@novartis.com

Source URL: <https://prod1.novartis.com/clinicaltrials/study/nct05142696>

List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT05142696>
2. #trial-eligibility
3. tel:215-728-5534
4. <mailto:Lakeesha.Dawson@fcc.edu>
5. tel:859-218-5151
6. <mailto:daria.brausch@uhhospitals.org>
7. tel:706-353-5006
8. <mailto:laurie.bridges@universitycancer.com>
9. tel:732-836-4190
10. <mailto:dunluchen@hackensackumc.org>
11. tel:202-687-8676
12. <mailto:aew72@georgetown.edu>
13. tel:+41613241111
14. <mailto:>
15. tel:1-888-669-6682
16. <mailto:novartis.email@novartis.com>